1.
Global tuberculosis report 2017 [WHO/HTM/TB/2017.23] Available from: http://apps​.who.int/iris​/bitstream/10665​/259366/l/9789241565516-eng.pdf?ua=1 World Health Organization: Geneva. 2017.
2.
WHO handbook for guideline development – 2nd ed. Available from: http://apps​.who.int/iris​/bitstream/10665​/145714/1/9789241548960eng.pdf. World Health Organization: Geneva. 2014.
3.
Schünemann H, Brozek J, Gordon Guyatt G, Andrew Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [Internet], 2013 [Updated October 2013] Available from: https://gdt​.gradepro​.org/app/handbook/handbook.html. 2013.
4.
WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision [WHO/HTM/TB/2016.04], Available from: http://apps​.who.int/iris​/bitstream/10665​/250125/1/9789241549639-eng.pdf. World Health Organization: Geneva. 2016. [PubMed: 27748093]
5.
Guidelines for the programmatic management of drug-resistant tuberculosis [WHO/HTM/TB/2006.361]. Available from: http://apps​.who.int/iris​/bitstream/10665​/246249/2/9789241546959-eng.pdf. World Health Organization: Geneva. 2006.
6.
Guidelines for the programmatic management of drug-resistant tuberculosis - Emergency update [WHO/HTM/TB/2008.402]. Available from: http://apps​.who.int/iris​/bitstream/10665​/43965/1/9789241547581eng.pdf. World Health Organization: Geneva. 2008.
7.
Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [WHO/HTM/TB/2014.11]. Available from: http://apps​.who.int/iris​/bitstream/10665​/130918/1/9789241548809eng.pdf. World Health Organization: Geneva. 2014. [PubMed: 25320836]
8.
Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children [WHO/HTM/TB/2013.16]. Available from: http://apps​.who.int/iris​/bitstream/1Q665​/112472/1/9789241506335eng.pdf?ua=l. World Health Organization: Geneva. 2013. [PubMed: 25473701]
9.
The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin [WHO/HTM/TB/2016.12]. Available from: http://apps​.who.int/iris​/bitstream/10665​/250586/1/9789241511261-eng.pdf?ua=1. World Health Organization: Geneva. 2016.
10.
Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero J. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2016;20(8):1099-1104. [PMC free article: PMC5310937] [PubMed: 27393546]
11.
Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2017;17(2):223-234. [PubMed: 27865891]
12.
Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. [PMC free article: PMC3700922] [PubMed: 23843980]
13.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. New England Journal of Medicine. 2014;371(17):1588-1598. [PubMed: 25337748]
14.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. New England Journal of Medicine. 2014;371(17): 1577-1587. [PMC free article: PMC4277680] [PubMed: 25196020]
15.
Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in M-T. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS One. 2016;11(3):e0151724 (https://www​.ncbi.nlm​.nih.gov/pubmed/27022741, accessed. [PMC free article: PMC4811416] [PubMed: 27022741]
16.
The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions Version 5.1.0. [updated March 2011]. Available from: http://handbook-5-1​.cochrane.org/. John Wiley & Sons. 2011.
17.
Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A et al. Rating quality of evidence and strength of recommendations: Going from evidence to recommendations. BMJ: British Medical Journal. 2008;336(7652):1049. [PMC free article: PMC2376019] [PubMed: 18467413]
18.
Tugwell P, Knottnerus JA. Advantages of individual patient data analysis in systematic reviews. Journal of clinical epidemiology. 2010;63(3):233-234. [PubMed: 20152706]
19.
Stewart LA, Tierney JF, Clarke M. Reviews of individual patient data. In: Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series 2008 Sep 22. John Wiley & Sons, Ltd, Chichester, UK, John Wiley & Sons, Ltd, Chichester, UK. 2008.
20.
Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. The Lancet Infectious Diseases. 2016;16(10):1185-1192. [PMC free article: PMC5030278] [PubMed: 27397590]
21.
The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance [WHO/HTM/TB/2016.07]. Available from: http://apps​.who.int/iris​/bitstream/10665​/246131/1/9789241510561-eng.pdf?ua=1. World Health Organization: Geneva. 2016.
22.
Ramachandran G, Kumar AH, Srinivasan R, Geetharani A, Sugirda P, Nandhakumar B et al. Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. The Indian journal of medical research. 2012;136(6):979. [PMC free article: PMC3612327] [PubMed: 23391793]
23.
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101-119 (https://www​.ncbi.nlm​.nih.gov/pubmed/9068926, accessed. [PubMed: 9068926]
24.
University of Liverpool. HIV drug interaction checker [Updated December 2017]. Available from: https://www​.hiv-druginteractions​.org/checker.
25.
Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Scientific Reports. 2018;8(1):3246. [PMC free article: PMC5818527] [PubMed: 29459669]
26.
Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update [WHO/HTM/TB/2017.05]. Available from: http://apps​.who.int/iris​/bitstream/10665​/255052/1/9789241550000-eng.pdf?ua=1. World Health Organization: Geneva. 2017.
27.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A et al. Official American Thoracic Society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases. 2016;63(7):e147-e195. [PMC free article: PMC6590850] [PubMed: 27516382]
28.
Global Drug Facility (GDF) catalogueProducts List. Available from: http://www​.stoptb.org​/gdf/drugsupply/drugs_available.asp. Stop TB Partnership: Geneva.
29.
Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) [WHO/HTM/TB/2013.2]. Available from: http://apps​.who.int/iris​/bitstream/10665​/79199/1/9789241505345_eng.pdf. World Health Organization: Geneva. 2013.
30.
Guidance for national tuberculosis programmes on the management of tuberculosis in children [WHO/HTM/TB/2014.03]. Available from: http://apps​.who.int/iris​/bitstream/10665​/112360/1/9789241548748_eng.pdf?ua=1. Geneva: World Health Organization. 2014. [PubMed: 24999516]
31.
Blumberg H, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine. 2003;167(4):603. [PubMed: 12588714]
32.
Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clinical Infectious Diseases. 2012;55(8):1154-1163. [PubMed: 22820541]
33.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach, 2nd ed. Available from: http://apps​.who.int/iris​/bitstream/10665​/208825/1/9789241549684_eng.pdf?ua=1. World Health Organization: Geneva. 2016. [PubMed: 27466667]
34.
Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. CHEST Journal. 2001;119(6):1730-1736. [PubMed: 11399698]
35.
Nolan C, Goldberg S. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. The International Journal of Tuberculosis and Lung Disease. 2002;6(11):952-958. [PubMed: 12475140]
36.
Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Lim SY et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC infectious diseases. 2008;8(1):6. [PMC free article: PMC2245946] [PubMed: 18211720]
37.
Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. Journal of Antimicrobial Chemotherapy. 2011;66(7):1431-1446. [PMC free article: PMC3112029] [PubMed: 21586591]
38.
Centers for Disease Control and Prevention (Atlanta). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. MMWR. Morbidity and mortality weekly report. 2001;50(34):733. [PubMed: 11787580]
39.
Voogt G, Schoeman H. Ototoxicity of aminoglycoside drugs in tuberculosis treatment. The South African journal of communication disorders= Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings. 1996;43:3-6. [PubMed: 9265840]
40.
Gülbay BE, Gürkan ÖU, Yıldız ÖA, Önen ZP, Erkekol FÖ, BaÇÇıoğlu A et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory medicine. 2006;100(10):1834-1842. [PubMed: 16517138]
41.
Bloss E, Kukša L, Holtz T, Riekstina V, Skripčonoka V, Kammerer S et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. The International Journal of Tuberculosis and Lung Disease. 2010;14(3):275-281. [PubMed: 20132617]
42.
Oxlade O, Falzon D, Menzies D. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. European Respiratory Journal. 2012;39(3):626-634. [PubMed: 21828030]
43.
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS medicine. 2012;9(8):e1001300. [PMC free article: PMC3429397] [PubMed: 22952439]
44.
Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis [WHO/HTM/TB/2017.13]. Available from: http://apps​.who.int/iris​/bitstream/10665​/259180/1/9789241512572-eng.pdf. World Health Organization: Geneva. 2017.